Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 2/20 | 0.39 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 2/20 | 0.35 |
| ▸ | TYK2 | P29597 | 2/20 | 0.35 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23815877 | 0.81 | AURKA (0.35) | PDPK1JAK2FGFR1DYRK1A | |
| SCHEMBL27188390 | 0.79 | PDPK1 (0.33) | PDPK1JAK2FGFR1 | |
| SCHEMBL29589071 | 0.79 | PDPK1 (0.43) | PDPK1 | |
| SCHEMBL25457789 | 0.73 | — | — | |
| SCHEMBL19544911 | 0.72 | PDPK1 (0.42) | PDPK1JAK1TYK2JAK3JAK2 | |
| SCHEMBL11745813 | 0.67 | KDR (0.42) | PDPK1JAK1TYK2JAK3JAK2 | |
| SCHEMBL22755090 | 0.66 | ATAD2 (0.43) | ATAD2 | |
| SCHEMBL19533293 | 0.66 | JAK1 (0.36) | JAK1TYK2JAK3JAK2LMNA | |
| SCHEMBL8290236 | 0.64 | NOS3 (0.38) | LMNA | |
| SCHEMBL24728843 | 0.64 | CHEK1 (0.44) | PDPK1FGFR1PRMT5WDR77DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145305-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| WO-2021180107-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2021-09-16 | — | — | WO | disclosed |
| EP-3246317-A1 | BTK INHIBITOR | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. (CN) | 2017-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145305-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | PDPK1 60/4885ATAD2 2908/4885JAK1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.